Table 5 Candidate gene list identified within the mapped QTL, Mom19–27, based on merge analysis and using MGI data base
Trait | Chromosome | Mom | Gene | |
|---|---|---|---|---|
SB2 | 16 | Mom 22 / Mom 23 | Eih3 | ethanol induced hypothermia 3 |
Mom 22 / Mom 23 | Bwtn1 | body weight at necropsy 1 | ||
Mom 22 / Mom 23 | Aod1a | autoimmune ovarian dysgenesis 1a | ||
Mom 22 / Mom 23 | Skts-fp3 | skin tumor susceptibility in FVB and PWK 3 | ||
Mom 22 / Mom 23 | Eae41 | experimental allergic encephalomyelitis susceptibility 41 | ||
Mom 22 / Mom 23 | Diobq | diet-induced obesity QTL | ||
Mom 22 / Mom 23 | Dice1b | determination of interleukin 4 commitment 1b | ||
Mom 23 | Eae11 | experimental allergic encephalomyelitis susceptibility 11 | ||
Mom 23 | Lith14 | lithogenic gene 14 | ||
Mom 23 | Pod | plasticity of ocular dominance | ||
Sluc27 | susceptibility to lung cancer 27 | |||
Etia | ethanol induced activation | |||
Bpq9 | blood pressure QTL 9 | |||
Tgq28 | triglyceride QTL 28 | |||
Pgia10 | proteoglycan induced arthritis 10 | |||
SB3 | 9 | Mom 26 | Sles4 | systemic lupus erythmatosus suppressor 4 |
Mom 26 | Bmiq8 | body mass index QTL 8 | ||
Mom 26 | Obq5 | obesity QTL 5 | ||
Mom 26 | Igan3 | IgA nephropathy 3 | ||
Mom 26 | Elnv | epilepsy naive | ||
Mom 26 | V125Dq7 | vitamin D active form serum level QTL 7 | ||
Mom 26 | V125Dq8 | vitamin D active form serum level QTL 8 | ||
SB3 | 10 | Mom 21 | Obsty3 | obesity 3 |
Mom 21 | Sysbp1 | systolic blood pressure 1 | ||
Mom 21 | W3q11 | weight 3 weeks QTL 11 | ||
W6q6 | weight 6 weeks QTL 6 | |||
Mom 21 | W10q5 | weight 10 weeks QTL 5 | ||
Mom 21 | Egq7 | early growth QTL 7 | ||
Mom 21 | Hrtq3 | heart weight QTL 3 | ||
Mom 21 | Kidpq2 | kidney weight percentage QTL 2 | ||
Mom 21 | Lvrq4 | liver weight QTL 4 | ||
Mom 21 | Scfpq1 | subcutaneous fat pad percentage QTL 1 | ||
Scc9 | colon tumor susceptibility 9 | |||
Eae34 | experimental allergic encephalomyelitis susceptibility 34 | |||
Lmblgq4 | limb length QTL 4 | |||
Lmblgq4 | limb length QTL 4 | |||
Angvq1 | angiogenesis by VEGF QTL 1 | |||
Phl2 | progressive hearing loss 2 | |||
Cia8 | collagen induced arthritis QTL 8 | |||
Wght9 | weight 9 | |||
Bbaa18 | B.burgdorferi-associated arthritis 18 | |||
Skull14 | skull morphology 14 | |||
Lmb4 | lupus in MRL and B6 F2 cross, QTL 4 | |||
Lifespan2 | life span 2 | |||
Pbwg16 | postnatal body weight growth 16 | |||
Hpcr2 | hepatocarcinogen resistance 2 | |||
Jckm3 | juvenile cystic kidney modifier 3 | |||
Ath17 | atherosclerosis 17 | |||
Eae17 | experimental allergic encephalomyelitis susceptibility 17 | |||
Hfhl4 | high-frequency hearing loss 4 | |||
Clfrhl1 | click-frequency hearing loss 1 | |||
Lfhl1 | low-frequency hearing loss 1 | |||
Mfhl1 | medium-frequency hearing loss 1 | |||
Obrq12 | obesity resistance QTL 12 | |||
Pcholq4 | plasma cholesterol QTL 4 | |||
Gluq1 | blood glucose QTL 1 | |||
Bsc1 | brain size control 1 | |||
El3 | epilepsy 3 | |||
Insq9 | insulin QTL 9 | |||
Aem3 | anti-erythrocyte autoantibody modifier 3 | |||
Ssrq4 | stress response QTL 4 | |||
Pwgrq19 | post-weaning growth rate QTL 19 | |||
Tesq3 | testis weight QTL 3 | |||
Espq3 | embryo survival preimplantation QTL 3 | |||
Estoq3 | embryo survival total QTL 3 | |||
Egq9 | early growth QTL 9 | |||
Lgaq5 | late growth adjusted QTL 5 | |||
W10q8 | weight 10 weeks QTL 8 | |||
W6q8 | weight 6 weeks QTL 8 | |||
Cia29 | collagen induced arthritis QTL 29 | |||
Igf1sl2 | IGF-1 serum levels 2 | |||
Ltpr5a | Leishmania tropica response 5a | |||
Ltpr5 | Leishmania tropica response 5 | |||
Lgth11 | body length 11 | |||
Vtbt9 | vertebral trabecular bone trait 9 | |||
Fembrs3 | femur breaking strength 3 | |||
Ednrbm1 | endothelin receptor type B modifier 1 | |||
Tmevp2 | Theiler’s murine encephalomyelitis virus persistence 2 | |||
Ogrq4 | overall growth rate QTL 4 | |||
Femwf3 | femur work to failure 3 | |||
SB3 | 12 | Pifs1 | peptide-induced fatal syndrome 1 | |
Tcq14 | total cholesterol QTL 14 | |||
Bmiq11 | body mass index QTL 11 | |||
Chldq7 | cholesterol and HDL QTL 7 | |||
Tglq5 | triglyceride QTL 5 | |||
Femwf9 | femur work to failure 9 | |||
Tmc1m3 | Tmc1 modifier 3 | |||
Total Polyps | 16 | Mom 23 | Eae11 | experimental allergic encephalomyelitis susceptibility 11 |
Mom 22 | Arrd3 | age-related retinal degeneration 3 | ||
Mom 22 / Mom 23 | Aod1a | autoimmune ovarian dysgenesis 1a | ||
Tauph | tau phosphorylation | |||
Mom 23 | Lith14 | lithogenic gene 14 | ||
Mom 22 | Remslp3 | rapid eye movement sleep 3 | ||
Etia | ethanol induced activation | |||
Pgia10 | proteoglycan induced arthritis 10 | |||
Renf2 | renal failure 2 | |||
Sluc27 | susceptibility to lung cancer 27 | |||
Bpq9 | blood pressure QTL 9 | |||
Mom 22 | Pcd4ts3 | p-glycoprotein positive CD4 T cell subset 3 | ||
Mom 22 | Ipng3 | imprinted postnatal growth 3 | ||
Tgq28 | triglyceride QTL 28 | |||
Mom 23 | Imraq3 | immune response to AAV2 QTL 3 | ||
Mom 22 / Mom 23 | Diobq | diet-induced obesity QTL | ||
Mom 22 / Mom 23 | Bwtn1 | body weight at necropsy 1 | ||
Mom 22 | Lp1 | lymphocyte proliferation 1 | ||
Mom 22 / Mom 23 | Dice1b | determination of interleukin 4 commitment 1b | ||
Lmr18 | leishmaniasis resistance 18 | |||
Mom 23 | Pod | plasticity of ocular dominance | ||
Mom 22 / Mom 23 | Eih3 | ethanol induced hypothermia 3 | ||
Mom 22 / Mom 23 | Skts-fp3 | skin tumor susceptibility in FVB and PWK 3 | ||
Cocia19 | cocaine-induced activity, QTL 19 | |||
Lmr18a | leishmaniasis resistance 18a | |||
Lmr18b | leishmaniasis resistance 18b | |||
Mom 22 / Mom 23 | Eae41 | experimental allergic encephalomyelitis susceptibility 41 | ||
Total Polyps | 12 | Ath6 | atherosclerosis 6 | |
Circp1 | circadian photosensitivity 1 | |||
Cplaq10 | circadian period of locomotor activity 10 | |||
Pifs1 | peptide-induced fatal syndrome 1 | |||
Tcq14 | total cholesterol QTL 14 | |||
Bmiq11 | body mass index QTL 11 | |||
Chldq7 | cholesterol and HDL QTL 7 | |||
Tglq5 | triglyceride QTL 5 | |||
Femwf9 | femur work to failure 9 | |||
Tmc1m3 | Tmc1 modifier 3 |